Synthego Corp., a provider of genome engineering solutions, opened its state-of-the-art GMP synthesis facility. The new 18,000 square-foot facility supports the growing demand for development of high-quality, CRISPR-enabled in vivo and ex vivo therapeutics by pharma and biopharma clients, including via IND and NDA or BLA enabling clinical studies. The cGMP facility features 24/7 operations with advanced equipment and technologies, including multiple multiplexed manufacturing lines, fully auto...